華潤醫藥(03320.HK)中期實現淨利潤55.4億元 同比增長10.2%
格隆匯8月29日丨華潤醫藥(03320.HK)宣佈,2024年中期,集團錄得總收益達人民幣128,597.6百萬元,較上年同期總收益人民幣122,818.4百萬元增長4.7%。2024年上半年,製藥、醫藥分銷、藥品零售三個集團主要業務分部的收益佔比分別為16.5%、79.6%以及3.9%。
報吿期內,集團實現毛利人民幣20,933.5百萬元,較2023年上半年的毛利人民幣19,760.6百萬元增長5.9%。2024年上半年的整體毛利率為16.3%,與2023年上半年毛利率16.1%相比提高0.2個百分點,主要受益於報吿期內製藥業務毛利率水平提升。
報吿期內,集團實現淨利潤人民幣5,540.6百萬元,較2023年上半年的淨利潤人民幣5,029.1百萬元增長10.2%。集團實現公司擁有人應占溢利人民幣2,604.8百萬元,較2023年上半年公司擁有人應占溢利人民幣2,681.7百萬元減少2.9%。報吿期內每股基本盈利為人民幣0.41元。
為了提升股東回報,董事會決議宣派中期股息每股港幣0.0908元或人民幣0.083元,此次為公司首次宣派中期股息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.